We are live on ! Find out more
Alyeska Investment Group

Alyeska Investment Group Portfolio holdings

AUM $35.4B
1-Year Est. Return 33.54%
This Fund
S&P 500
This Quarter Est. Return
-0.95%
1 Year Est. Return
+33.54%
3 Year Est. Return
+101.08%
5 Year Est. Return
+102.29%
10 Year Est. Return
+544.32%
AUM
$10.9B
AUM Growth
+$1.47B
Cap. Flow
+$1.54B
Cap. Flow %
14.16%
Top 10 Hldgs %
12.66%
Holding
527
New
158
Increased
123
Reduced
88
Closed
149

Sector Composition

Rank Sector Weight
1 Technology 16.1%
2 Healthcare 14.81%
3 Industrials 13.15%
4 Financials 12%
5 Consumer Discretionary 9.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CUDA
351
DELISTED
Barracuda Networks, Inc.
CUDA
$1.11M 0.01%
72,251
-483,253
-87% -$6.16M
RDWR icon
352
Radware
RDWR
$1.19B
$1.1M 0.01%
+93,203
New +$1.12M
LRMR icon
353
Larimar Therapeutics
LRMR
$432M
$1.03M 0.01%
12,899
-1,277
-9% -$101K
NGNE icon
354
Neurogene
NGNE
$712M
$1.02M 0.01%
5,779
+1,379
+31% +$268K
NRF
355
DELISTED
NorthStar Realty Finance Corp.
NRF
$858K 0.01%
65,403
-3,163,341
-98% -$38.8M
RLYP
356
DELISTED
RELYPSA INC COM
RLYP
$853K 0.01%
62,944
+12,944
+26% +$220K
DARE icon
357
Dare Bioscience
DARE
$21M
$848K 0.01%
2,607
+81
+3% +$22.8K
SVRA icon
358
CALL
Savara
SVRA
$1.19B
$810K 0.01%
42,420
WINT
359
DELISTED
Windtree Therapeutics Inc
WINT
$760K 0.01%
454,821
+12,858
+3% +$27.6K
ATRS
360
DELISTED
Antares Pharma, Inc.
ATRS
$739K 0.01%
849,224
+26,255
+3% +$25.4K
VTVT icon
361
vTv Therapeutics
VTVT
$139M
$664K 0.01%
3,216
-93
-3% -$23.2K
BURL icon
362
Burlington
BURL
$23.2B
$622K 0.01%
+11,067
New +$578K
BLRX
363
BioLineRX
BLRX
$11.8M
$612K 0.01%
999
+258
+35% +$162K
BIOA
364
CALL
DELISTED
BioAmber Inc.
BIOA
$539K 0.01%
128,351
+3,968
+3% +$16.7K
VNCE icon
365
Vince Holding Corp
VNCE
$86.8M
$486K ﹤0.01%
7,684
-17,016
-69% -$953K
CTIC
366
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$411K ﹤0.01%
77,347
+2,347
+3% +$18.8K
TTHI
367
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$374K ﹤0.01%
292,352
+9,037
+3% +$10.4K
UVE icon
368
Universal Insurance Holdings
UVE
$1.23B
$368K ﹤0.01%
+20,700
New +$384K
BLPH
369
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$354K ﹤0.01%
9,599
+297
+3% +$11K
PARN
370
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$314K ﹤0.01%
147,458
-43,043
-23% -$119K
WINT
371
CALL
DELISTED
Windtree Therapeutics Inc
WINT
$298K ﹤0.01%
178,570
-1
-0% -$2
NTBL
372
CALL
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$290K ﹤0.01%
2,381
ALPN
373
DELISTED
Alpine Immune Sciences Inc
ALPN
$275K ﹤0.01%
16,510
+3,841
+30% +$76.9K
BIND
374
CALL
DELISTED
BIND THERAPEUTICS INC
BIND
$253K ﹤0.01%
114,786
RLJE
375
CALL
DELISTED
RLJ Entertainment, Inc.
RLJE
$170K ﹤0.01%
66,667

Similar funds

Alyeska Investment Group's Q1 2016 Portfolio in Review

As of Q1 2016, Alyeska Investment Group held 527 positions worth $10.9B, up 16% from $9.41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Alyeska Investment Group deployed $1.54B of net new capital in Q1 2016, opening 158 new positions and adding to 123 existing holdings. Its largest new stake was Bausch Health: 2,200,000 shares worth $57.9M.

By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Amdocs, an estimated $66.8M trimmed.

  • Alyeska Investment Group's largest Q1 2016 buy was Bausch Health: 2,200,000 shares worth $57.9M.
  • Alyeska Investment Group added most to Devon Energy in Q1 2016, an estimated $117M increase.
  • Alyeska Investment Group's biggest Q1 2016 reduction was Amdocs, cutting an estimated $66.8M.
  • Alyeska Investment Group fully exited PRECISION CASTPARTS CORP in Q1 2016, selling an estimated $93.6M.
  • Alyeska Investment Group's ten largest holdings make up 13% of its $10.9B portfolio in Q1 2016.
  • Alyeska Investment Group opened 158 new positions and closed 149 in Q1 2016.
  • Alyeska Investment Group's portfolio value rose 16% quarter-over-quarter to $10.9B.

Based on Alyeska Investment Group's 13F filing for Q1 2016, filed 16 May 2016.